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ABSTRACT
OBJECTIVE: The objective of this selective evidence based medicine review is to determine
whether or not oral gabapentin administered prior to scheduled cesarean delivery decreases pain
with movement in adult women at 24 hours postpartum as compared to placebo. DESIGN:
Review of three English language, peer-reviewed, primary studies published after 2000.
SOURCES: Three randomized, placebo-controlled trials comparing the efficacy of oral
gabapentin to a lactose placebo in adult women undergoing elective cesarean delivery. Sources
were selected from PubMed, Medline, Ovid, and the Cochrane Database to include all studies
matching the keywords that were published in peer-reviewed, English language journals after
2000 and included only women over 18 years of age. OUTCOMES MEASURED: Primary
outcome measured was patient reported pain perception on a 0-100mm Visual Analog Scale
(VAS - 0 = no pain, 100 = worst possible pain) measured 24 hours post cesarean section.
Satisfaction with pain management, as measured by a numerical rating scale (0-10) was
considered secondarily. RESULTS: Two of the three studies found significant improvement in
post-cesarean delivery analgesia and satisfaction with analgesia with adjunctive gabapentin
therapy at doses of 600mg and 300mg respectively. A third study investigated both dosages, but
found no clinical benefit to either. CONCLUSIONS: Evidence is inconclusive as to whether oral
gabapentin administered prior to scheduled cesarean delivery decreases pain with movement in
adult women at 24 hours postpartum as compared to placebo.
KEY WORDS: Gabapentin, Pregnancy, Cesarean Section, Cesarean Delivery.
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INTRODUCTION
Cesarean delivery is the most commonly performed surgical procedure in the United
States and accounts for roughly 30% of all deliveries.1 While traditionally indicated for high-risk
pregnancies in which vaginal delivery would result in increased maternal or fetal mortality, it has
become increasingly common in recent decades as women without medical indication request the
procedure. Estimates of prevalence for cesarean delivery by maternal request are as high as 18%
of all deliveries worldwide and 2.5% in the United States.1,2 Patient reported reasons for elective
cesarean delivery include convenience of scheduled delivery, fear of pain and childbirth, as well
as poor past experiences with spontaneous vaginal delivery.2 Additionally, elective cesarean
delivery proffers a number of medical benefits to both the mother and fetus, including decreased
risk of pelvic floor injury, fetal shoulder dystocia, maternal-fetal transmission of herpes simplex
virus and human immunodeficiency virus, and late-term still birth.2
Despite the benefits, cesarean delivery also presents a number of unique risks to both
mother and fetus. Studies indicate that patients are most concerned about intra- and postoperative pain from cesarean delivery, and for good reason; one of the most commonly reported
complications from cesarean delivery is pain.3 The mechanism for this is not well understood.
Contributing factors may include unopposed central sensitization of nociceptors, neuropathic
sensitization following nerve entrapment, and incision type.4 Access to the abdomen and uterus
is typically gained via a Pfannenstiel-type incision, which may result in entrapment of the
iliohypogastric and ilioinguinal nerves and chronic pelvic pain months after the procedure.4,5
Cesarean section pain is typically managed with a combination of anesthetics and
analgesics. Intra-operative bupivacaine is most commonly employed for spinal anesthesia, while
lidocaine with epinephrine is most commonly employed in epidural anesthesia; both may be used
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with adjunctive opioids or fentanyl to provide analgesia for 18-24 hours.6 Post-operative
analgesia is typically achieved with a multimodal approach including patient-controlled IV
morphine, non-steroidal anti-inflammatory drugs, and acetaminophen.6
Opioid analgesia, however, poses many potential risks and may be inappropriate in
patients who are opioid naïve, have allergies to opiates, or suffer from an opiate addiction.7,8
Morphine products like Astramorph/PF, Infumorph, and Duramorph, carry warnings for
overdose and resuscitation in the setting of epidural/intrathecal administration, and their use postoperatively have been noted to negatively affect the heart rate of the fetus and result in
respiratory depression of the breastfeeding newborn.7 These findings are supported by studies
demonstrating a longer time to first interaction between mother and baby, longer times to breast
feeding, decreased ability to breast feed, decreased maternal-fetal bonding, and decreased
satisfaction with the birthing experience associated with opioid pain management following
cesarean delivery.3,8,9
Furthermore, chronic pain following cesarean delivery has substantial impact on the cost
of healthcare. In 2008, cesarean delivery with complications, such as prolonged pain, resulted in
an additional two days hospitalization over vaginal delivery (mean 4.5 days vs. 2.6 days) and
accounted for 46% of hospital delivery costs.10 Of those deliveries with complications, it is
estimated that 12.3% specifically result in debilitating pain that affects infant care within the first
6 months postpartum, accounting for $3.1 billion of hospital delivery costs.10
With the number of adverse effects and the overwhelming costs of care associated with
chronic, debilitating pain following cesarean delivery, alternative methods of pain control are
essential. Gabapentin, a centrally-acting calcium channel alpha 2-delta ligand used in the
management of neuropathic pain, is a relatively safe alternative that has been shown to be
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effective in decreasing acute post-surgical pain in similar procedures, such as total
hysterectomy.8 Although classified as pregnancy category C, studies have yet to demonstrate
increased maternal-fetal risk from gabapentin exposure within hours of delivery. Gabapentin is
excreted in breast milk at a rate of 1 mg/kg/day; the effect that this has on newborns is
unknown.7

OBJECTIVE
The objective of this selective EBM review is to determine whether or not oral gabapentin
administered prior to scheduled cesarean delivery decreases pain with movement in adult women
at 24 hours postpartum as compared to placebo.

METHODS
Three studies were included in the analysis. All studies were randomized, double-blind,
placebo-controlled trials investigating the efficacy of oral gabapentin administered prior to
delivery compared to a visually-matched, lactose placebo in adult women undergoing elective
cesarean delivery. The primary outcome measured was pain with movement at 24 hours postoperation. Studies also measures satisfaction with pain management. 8,11,12
Sources were queried from PubMed, Medline, Cochrane Database, and OVID to include
English-language studies of adult women in peer-reviewed journals published after 2000.
Articles were selected by the author based on their relevance to the clinical question. Articles
were excluded if they were published outside of the search window, were not published in a
peer-reviewed publication, were not in English, or included women younger than 18 years of
age. Additionally, articles were excluded if they had appeared in prior meta-analyses or
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systematic reviews of similar clinical inquiries. Key words included gabapentin, pregnancy,
cesarean delivery, and cesarean section.

OUTCOMES MEASURED
The primary outcome for all three studies was patient reported pain perception with
movement as measured by a 0-100mm Visual Analog Scale (VAS - 0 = no pain, 100 = worst
possible pain) 24 hours post cesarean section. 8,11,12 Moore et al8 and Short et al12 further defined
primary outcomes as VAS scores 6, 12, and 48 hours post-cesarean section with movement and
at rest, as well as at three months post-operatively. Anaraki et al11 also defined primary outcomes
as time to first request for supplemental analgesia and total dose of supplemental analgesia
required.
Secondary measures varied by study. All three studies measured patient satisfaction with
intra- and post-operative analgesia. 8,11,12 Moore et al8 and Anaraki et al11 utilized a 0-10
numerical rating scale (NRS). Short et al12 used a 0-100 VAS (0 = not satisfied, 100 =
completely satisfied). Safety and tolerability were assessed by Moore et al8 and Short et al12
using a patient reported numerical rating scale of 0-3 for level of sedation, nausea, vomiting,
dizziness, and pruritus. Anaraki et al11 do not explicitly monitor for safety and tolerability, but
report nursing assessments of nausea, sedation, and pruritus.

RESULTS
Study Designs and Subject Selection
Study subjects were enrolled from either an internationally-regarded Canadian tertiary
care hospital8,12 or a Middle-Eastern teaching hospital.11 Subjects were English-speaking women
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over 18 years of age presenting at term for elective cesarean delivery on an inpatient basis.
Gravity and parity were null factors in subject selection in two studies;8,12 the third excluded all
multiparous women.11 Patients were excluded from participation if they had moderate to severe
systemic illness as evidenced by an ASA Physical Status Score of 3 or greater; infectious
diseases, including HIV and hepatitis; uncontrolled hypertension or diabetes mellitus;
contraindications to neuraxial anesthesia/study medications; or had taken pain medications one
week prior to surgery. Patients were also excluded if they were known IV drug users or were
carrying fetuses with known congenital abnormalities. All three studies utilized a
demographically-matched placebo-controlled group.8,11,12
Dosing of gabapentin varied by study, with Moore et al8 dosing 600mg orally, Anaraki et
al11 dosing 300mg orally, and Short et al12 dosing both 600mg and 300mg orally. The variable
dosing accounts for the lack studies demonstrating replicable therapeutic levels of gabapentin for
peri-operative pain and attempts to find the minimum necessary therapeutic dosage.6,7,12 One
study administered gabapentin two hours pre-operatively11 and the other two studies
administered the study drug one hour pre-operatively.8,12 Compliance was 100%, as only one
dose was required and was administered by study staff prior to surgery.
Intra-operative anesthesia was managed similarly across studies and consisted of either
0.75% bupivacaine 8,12 or 0.5% bupivacaine.11 Moore et al8 and Short et al12 augmented the
anesthesia with 10μg fentanyl and 100μg morphine, per hospital protocol, for all subjects,
regardless of study arm. Anaraki et al11 additionally administered 10μg fentanyl intrathecally to
the control group only to mitigate pain. In all studies, subjects were able to request additional
opioid analgesia post-operatively to augment pain management.
A summary of selected studies is presented in Table 1.
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Moore et al8
A total of 46 subjects were distributed evenly to each arm of the study, with two excluded
from analysis in the gabapentin group due to unblinding and spontaneous vaginal delivery. VAS
scores were compared using a repeated measures analysis of variance (ANOVA). Categorical
data, such as satisfaction and adverse event severity, were analyzed by χ2, Fisher exact test, or
Mann-Whitney U test. At 24 hours post cesarean delivery, the gabapentin group showed
significantly less pain with movement than the placebo group, with mean VAS scores (95% CI)
of 21mm (13-29) and 41mm (32-51), respectively (P = 0.001). Subjects in the gabapentin group
were also significantly more satisfied with their pain management than the subjects in the
placebo group at 24 hours (NRS, p=0.02). 5 subjects in each group requested supplemental
morphine. There was no significant difference in the amount of supplemental morphine dosed.
Mean total supplemental morphine (95% CI) for the gabapentin group was 4.2mg (1.1-7.2) and
3.2mg (1.0-5.4) for the placebo group (p=0.58).

Short et al 12
A total of 132 subjects were distributed evenly to each arm of the study, with 6 excluded
from analysis for failed spinal (3), protocol breach (2), or postponed procedure (1). VAS scores
were compared using a repeated measures analysis of variance (ANOVA) with Bonferroni
correction (pairwise α = 0.05 / 3 comparisons = 0.016) for multiple comparisons across the three
treatment groups. Categorical data, such as adverse event severity and NICU admission, were
analyzed by Fisher exact test or nonparametric Kruskal-Wallis tests.
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At 24 hours post cesarean delivery, there were no significant differences between groups
in pain scores with movement (overall p=0.61). Comparison of the 600mg gabapentin group to
the 300mg gabapentin group revealed improved pain control with the lower dose that was not
significant (mean difference = 5mm with 95% adjusted CI = -7 to 17). Comparison of 300mg to
placebo reveals a non-significant improvement in pain control (mean difference = -2mm with
95% adjusted CI = -14 to 10). 38 total subjects requested supplemental morphine. There was no
significant difference in the amount of supplemental morphine dosed. Mean total supplemental
morphine (95% CI) for the gabapentin 300mg group was 5.7mg (1.3-10.2), 6.7mg (4.7-8.8) for
the gabapentin 600mg group, and 7.9mg (5.9-9.9) for the placebo group (p=0.46).

Anaraki et al 11
A total of 78 subjects were distributed evenly to each arm of the study, with one excluded
from analysis in the gabapentin group due to failure of the spinal block. VAS scores, maternal
satisfaction, and supplemental morphine usage were analyzed by χ2 or Mann-Whitney U test. At
24 hours post cesarean delivery, the gabapentin group showed significantly less pain with
movement than the placebo group, with mean VAS scores (95% CI) of 24mm (13-30) and 38mm
(24-56), respectively (P = 0.001). Subjects in the gabapentin group were also significantly more
satisfied with their pain management than the subjects in the placebo group at 24 hours (NRS
mean (range) = 7 (4-10) gabapentin, 5 (1-9) placebo; p=0.001). Authors did not report how many
subjects in each group required supplemental morphine; however, in those subjects who did
receive supplemental morphine, the time to first dose was significantly longer in the gabapentin
group compared to placebo (mean hours (SD) = 4.59 (1.63) gabapentin, 2.65 (0.92) placebo;
p=0.000). Subjects in the gabapentin group requesting supplemental morphine also requested
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less than the placebo group. Mean total supplemental morphine (SD) for the gabapentin group
was 7.18mg (3.26) and 12.62mg (5.16) for the placebo group (p=0.000).

Safety and Tolerability
A well reported side effect of gabapentin use is sedation.7,12 The selected studies provide
further evidence for this effect. Moore et al8 demonstrate a significant difference in incidence of
severe sedation between gabapentin and placebo groups (19% vs. 0%, p=0.04) and note that
severe sedation occurred early, as there were no reports of sedation after 24 hours. Severe
sedation was not correlated with VAS pain ratings or satisfaction scales, although R values are
not reported.
Short et al12 refutes this claim, finding no increase in maternal sedation with either
600mg of gabapentin or a reduced dose of 300mg. They posit that the findings of the 2011 study
were the result of researcher bias. However, Anaraki et al11 document increased sedation at a
dose of 300mg compared to the placebo group (p=0.012).
Independent analyses of the combined reported adverse events in these three studies
supports this data (Table 2). The most deleterious adverse event encountered was nausea (NNH
= 27.2). Comparatively, sedation was relatively mild (NNH = 488.48) and pruritus least likely
(NNH = 767.96).
Neonatal outcomes were similar for all participants in all studies (Table 3).

DISCUSSION
Two of the three studies found significant improvement in post-cesarean delivery
analgesia and satisfaction with analgesia with adjunctive gabapentin therapy at doses of 600mg
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and 300mg respectively. 8,11 Dose finding studies in other surgical situations indicate that a
typical dose of 300-1200mg pre-operatively may be effective.12 Short et al varied the doses
accordingly, studying both 300 and 600mg doses, but found no clinical benefit.12
Gabapentin is capable of potentiating the effect of morphine, leading to prolonged
analgesia and marked CNS depression.7 While the included studies demonstrated relative safety
of the drug during labor and delivery and in the immediate postpartum period, patients must be
counseled about, and monitored for, common side effects of gabapentin administration, including
increased sedation, angioedema, multi-organ hypersensitivity (DRESS syndrome), and suicidal
ideation.7 Additionally, providers should use gabapentin with caution in patients with impaired
renal function, as gabapentin is renally-excreted.7
Moreover, care providers should take into consideration cost and coverage of drugs used
during labor and delivery. The wholesale cost for the dosages of gabapentin used in the included
studies are $252.62 per 100 tablets ($2.53/dose) for gabapentin 600mg and $133.20 per 100
tablets ($1.33/dose). This is in adjunct to the standard opiate analgesia, which is not inexpensive
($3.30 for 3mg epidural morphine; $0.11 for 100mcg intrathecal morphine).7
Limitations
Further research is warranted to address a number of issues among the studies. With a
limited sample size, the generalizability of the results to other women requesting cesarean
delivery is questionable. Although all three studies recorded the amount of supplemental
morphine administered per patient request, in depth analyses of these patients as their own subgroup were not conducted. None of the studies included women undergoing cesarean delivery on
a non-elective or emergent basis. Future study is warranted to evaluate the effects of oral
gabapentin in the management of these populations before routine use can be recommended.
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CONCLUSION
Evidence is inconclusive as to whether oral gabapentin administered prior to scheduled
cesarean delivery decreases pain with movement in adult women at 24 hours postpartum as
compared to placebo.
At the time of writing, recent publication of new data from Monks et al13 aims to clarify
many of these issues and finds that one pre-operative dose of gabapentin followed by 6 postoperative doses over two days produces modest improvement in pain scores and satisfaction with
pain management over control. This improvement comes at the expense of marked sedation,
casting the role of gabapentin in a multimodal approach to pain management for cesarean
delivery in doubt.
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Table 1 - Demographics & Characteristics of Selected Studies
Study
Type
#
Age (y) Inclusion
Exclusion
pts
>18y
• Full-term
• ASA Physical Status Score of ≥3
Moore Double 46
(mean
pregnant
• Contraindications to neuraxial anesthesia
(2011) -blind
RCT
= 34)
women
• History of HIV, hepatitis, uncontrolled
undergoing
hypertension, or diabetes mellitus
scheduled
• Known IVDU
cesarean
• Women with fetuses having known
delivery
congenital abnormalities
•>18 years
• Women having taken pain medications
one week prior to surgery
Double 132 >18y
• Full-term
• ASA Physical Status Score of ≥3
Short
(mean
women with
• Contraindications to neuraxial anesthesia
(2012) -blind
RCT
= 34.8) singleton
• History of epilepsy, central nervous
pregnancies
system or mental disorders, chronic pain,
undergoing
drug abuse, or use of neuropathic analgesics
scheduled
or antiepileptic drugs
cesarean
• Women with fetuses having known
delivery
congenital abnormalities
•>18 years
Anara
ki
(2014)

Double
-blind
RCT

78

>18y
(mean
= 27)

•Full term,
primiparous
women
undergoing
scheduled
cesarean
delivery
•>18 years

W/D

Interventions

2

Experimental: 600mg
gabapentin PO 1 hour
before surgery
Control: Lactose
placebo

6

• ASA Physical Status Score of ≥3
1
• Contraindications to neuraxial anesthesia
• History of smoking, hepatitis, chronic use
of gabapentin or opioids, psychological
problems, severe preeclampsia, and diabetes
mellitus
• Women with fetuses having known
congenital abnormalities

Experimental:
- 600mg gabapentin
PO 1 hour before
surgery;
- 300mg gabapentin
PO 1 hour before
surgery
Control: Lactose
placebo
Experimental: 300mg
gabapentin PO 2 hour
before surgery
Control: Lactose
placebo PO and 10ug
fentanyl IV
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Table 2. Safety and Tolerability of Gabapentin versus Lactose Placebo
CER (N)
EER (N)
RRI
ARI
NNH
NAUSEA
Cumulative 46 (107)
49 (105)
0.09
0.04
27.2
†
‡
Moore 2011 8 (23)
12 (21)
0.64
0.22
4.47
Short 2012, 600mg 19 (42)
19 (42)
0
0
0
Short 2012, 300mg 19 (42)
18 (42)
-0.05
-0.02
-42
Anaraki 2014 -----VOMITING
Cumulative 28 (145)
26 (143)
-0.06
-0.01
-88.61
Moore 2011 3 (23)
5 (21)
0.83
0.11
9.29
Short 2012, 600mg 10 (42)
7 (42)
-0.30
-0.07
-14
Short 2012, 300mg 10 (42)
10 (42)
0
0
0
Anaraki 2014 5 (38)
4 (38)
-0.22
-0.03
-34.47
SEDATION
Cumulative 65 (107)
64 (105)
0.003
0.002
488.48
Moore 2011 17 (23)
17 (21)
0.10
0.07
14.21
Short 2012, 600mg 24 (42)
23 (42)
-0.04
-0.02
-42
Short 2012, 300mg 24 (42)
24 (42)
0
0
0
Anaraki 2014 -----PRURITUS
Cumulative 86 (145)
85 (143)
0.002
0.001
767.96
Moore 2011 22 (23)
16 (21)
-0.20
-0.19
-5.14
Short 2012, 600mg 32 (42)
33 (42)
0.03
0.02
42
Short 2012, 300mg 32 (42)
36 (42)
0.13
0.1
10.5
Anaraki 2014 0 (38)
0 (38)
0
0
0
†
Moore 2011 – Gabapentin 600mg; Short 2012- Gabapentin 600mg; Anaraki 2014 –
Gabapentin 300mg
‡
Results rounded for simplicity of presentation. Calculations done without rounding.
Table 3. Neonatal Outcomes Across Studies
Moore et al8
Short et al12
Gaba Placebo Gaba
Gaba Placebo
300mg 600mg
N
21
23
42
42
42
a
Weight (g)
3520
3341
3429
3505
3382
1-minute Apgarb
9
9
9
9
9
b
5-minute Apgar
9
9
9
9
9
Umbilical artery
7.26
7.29
7.29
7.28
7.28
pHa
NICU admissionc
1
0
2
1
2
a
b
c
– Mean (SD)
– Median (range)
– Count

Anaraki et al11
Gaba
Placebo
38
-10
10
--

39
-10
10
--

--

--
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